Citation: | LI Zhiyan, LIU Jie, LI Bingyan, JIANG Cheng. Design, synthesis and evaluation of peptidomimetics targeting the polo-box domain of polo-like kinase 1[J]. Journal of China Pharmaceutical University, 2020, 51(3): 287-294. DOI: 10.11665/j.issn.1000-5048.20200305 |
[1] |
. Cell Mol Life Sci, 2010, 67(12): 1957-1970.
|
[2] |
de Cárcer G, Manning G, Malumbres M. From Plk1 to Plk5: functional evolution of polo-like kinases[J]. Cell Cycle, 2011, 10(14): 2255-2262.
|
[3] |
Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy[J]. Nat Rev Cancer, 2006, 6(4): 321-330.
|
[4] |
Lowery DM, Lim D, Yaffe MB. Structure and function of Polo-like kinases[J]. Oncogene, 2005, 24(2): 248-259.
|
[5] |
Golsteyn RM, Mundt KE, Fry AM, et al. Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function[J]. J Cell Biol, 1995, 129(6): 1617-1628.
|
[6] |
Lee KS, Burke TR
|
[7] |
Ma S, Liu MA, Yuan YL, et al. The serum-inducible protein kinase Snk is a G1 phase polo-like kinase that is inhibited by the calcium- and integrin-binding protein CIB[J]. Mol Cancer Res, 2003, 1(5): 376-384.
|
[8] |
Ma S, Charron J, Erikson RL. Role of Plk2 (Snk) in mouse development and cell proliferation[J]. Mol Cell Biol, 2003, 23(19): 6936-6943.
|
[9] |
Burns TF, Fei PW, Scata KA, et al. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (Taxol)-exposed cells[J]. Mol Cell Biol, 2003, 23(16): 5556-5571.
|
[10] |
Xie SQ, Xie B, Lee MY, et al. Regulation of cell cycle checkpoints by polo-like kinases[J]. Oncogene, 2005, 24(2): 277-286.
|
[11] |
Kong KL, Lu S, Gao YP, et al. Advances on the study of PLK1 inhibitors as antitumor agents[J]. J China Pharm Univ(中国药科大学学报), 2011, 42(1): 9-15.
|
[12] |
Yao AH, Chang YJ, Jiang C, et al. Research progress of Polo-like kinase 1 inhibitors targeting Polo-box domain[J]. J China Pharm Univ(中国药科大学学报), 2016, 47(1): 1-8.
|
[13] |
Yun SM, Moulaei T, Lim D, et al. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1[J]. Nat Struct Mol Biol, 2009, 16(8): 876-882.
|
[14] |
Liu F, Park JE, Qian WJ, et al. Peptoid-peptide hybrid ligands targeting the polo box domain of polo-like kinase 1[J]. ChemBioChem, 2012, 13(9): 1291-1296.
|
[15] |
Murugan RN, Park JE, Lim D, et al. Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1[J]. Bioorg Med Chem, 2013, 21(9): 2623-2634.
|
[16] |
Qian WJ, Park JE, Lee KS, et al. Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1)[J]. Bioorg Med Chem Lett, 2012, 22(24): 7306-7308.
|
[17] |
Ahn M, Han YH, Park JE, et al. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1[J]. J Med Chem, 2015, 58(1): 294-304.
|
[18] |
Hymel D, TRJrBurke. Phosphatase-stable phosphoamino acid mimetics that enhance binding affinities with the polo-box domain of polo-like Kinase 1[J]. ChemMedChem, 2017, 12(3): 202-206.
|
[19] |
Zhao XZ, Hymel D, Burke TR
|
[20] |
Chen YH, Li ZY, Liu Y, et al. Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1[J]. Bioorg Chem, 2018, 81: 278-288.
|
[21] |
Li ZY, Zhang ZG, Chen YH, et al. Design, synthesis and evaluation of d-amino acid-containing peptidomimetics targeting the polo-box domain of polo-like kinase 1[J]. Bioorg Chem, 2019, 85: 534-540.
|
[22] |
Li ZY, Zhang ZG, Sun HY, et al. Identification of novel peptidomimetics targeting the polo-box domain of polo-like kinase 1[J]. Bioorg Chem, 2019, 91: 103148.
|
[1] | LI Juanjuan, HUANG Yue, WANG Yahe, ZHANG Lianxiang, QIANG Yuanyuan, GUO Le, LIU Kunmei. Antiepileptic and neuroprotective mechanism of ursolic acid based on full-length transcriptome analysis[J]. Journal of China Pharmaceutical University, 2024, 55(4): 512-521. DOI: 10.11665/j.issn.1000-5048.2023111303 |
[2] | PEI Ting, WANG Yuying. Synthesis and preliminary anti-tumor activity of novel ursolic acid derivative-chalcone conjugates[J]. Journal of China Pharmaceutical University, 2017, 48(1): 31-41. DOI: 10.11665/j.issn.1000-5048.20170105 |
[3] | CHEN Hong, YANG Jie, CUI Wei-xi, WANG Qiang. Effects and mechanism of ursolic acid on lipopolysaccharide-induced THP-1 cells[J]. Journal of China Pharmaceutical University, 2011, 42(5): 447-451. |
[4] | WANG Jing-song, SHEN Jing, ZHANG Ting, TANG Cong, REN Tian-nian, XI Tao. Ursolic acid downregulates COX-2 expression by suppressing the activation of ERK in A549 cells[J]. Journal of China Pharmaceutical University, 2011, 42(1): 68-72. |
[5] | Inhibitory effects and mechanism of ursolic acid on the proliferation of rataortic smooth muscle cells[J]. Journal of China Pharmaceutical University, 2010, 41(1): 66-69. |
[6] | ZHENG Kai-bo, SUN Cheng-bin, MAO Hai-li, YANG Zai-bo. Progress in the research of chemical structural modification of ursolic acid and structure-activity relationship[J]. Journal of China Pharmaceutical University, 2009, 40(6): 580-584. |
[7] | Release and Identification of Monocrotalic Acid from Dehydromonocrotaline[J]. Journal of China Pharmaceutical University, 2003, (6): 18-21. |
[8] | Cloning of Spinach Glycolate Oxidase cDNA and Its Construction into Yeast Expression Vector[J]. Journal of China Pharmaceutical University, 2003, (1): 83-86. |
[9] | Cloning of S-adenosyl-L-methionine Synthetase Gene from Saccharomyces ceverisiae and its Expression in E.coli[J]. Journal of China Pharmaceutical University, 2002, (3): 87-89. |
[10] | Determination of Four Acids Components in Keyoulin Liquid Using Derivatization by GC[J]. Journal of China Pharmaceutical University, 1998, (6): 453-455. |
1. |
朱灵英,郭娟,张爱丽,王宝婕,曾礼芳,徐福荣,马晓惠. 参与植物三萜生物合成的细胞色素P450酶研究进展. 中草药. 2019(22): 5597-5610 .
![]() |